MRT-50969 / Monte Rosa Therap - LARVOL DELTA

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors (GlobeNewswire) - "MRT-50969 selectively inhibited proliferation and induced G1-S cell cycle arrest and senescence in CCNE1-amplified cancer cell lines, while sparing cell lines without amplification. When dosed orally as a single agent in preclinical models of CCNE1-amplified breast cancer and gastric cancer, the cyclin E1-directed MGD MRT-50969 induced robust tumor growth suppression and regression."

Preclinical • Solid Tumor